News for Liquidia Corporation (LQDA)

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points n Tuesday. The Dow traded up 0.13% to 42,817.81 while th...

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics' request for p

Liquidia Corporation (LQDA) commenced the first commercial shipment of YUTREPIAâ„¢ shortly after FDA approval. The court denied United Therapeutics' inj

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's LQDA Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for...

Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S.

Key Insights: Liquidia Corporation secures FDA approval for Yutrepia, while patent disputes loom.Analyst price targets suggest significant upside potential for

Liquidia Corporation (LQDA) faces new patent litigation from United Therapeutics (UTHR) over the '782 patent. The litigation seeks to block commercializ

New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR's ”˜782 patent and seeks to

Liquidia Corporation (NASDAQ:LQDA) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsJason Adair - Chief Business OfficerRoger...

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NLQDA.OQ - Liquidia CorpQ1 2025 Liquidia Corp Earnings CallMay 08, 2025 / 12:30PM GMT =========

Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter compared to -7.7% return for iShares Russell 2000 Value Index and -9.5% return for the iShares Russell 2000 Index. In the quarter, Donald Trump’s […]

**media[618707]**

MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation ( LQDA), a biopharmaceutical company developing innovative therapies for patients wit

Liquidia Corporation (LQDA) has successfully defended its amendment to the New Drug Application for YUTREPIA inhalation powder, following a legal decision by Ju

**media[613241]**

**media[548306]**

Transaction Overview On February 20, 2025, Whitefort Capital Management, LP (Trades, Portfolio) executed a strategic stock transaction involving Arbutus Biophar

If PH-ILD studies translate into the real world, the market opportunity for Liquidia is enormous. Where should we expect LQDA stock to be in the next few months? Find out.

Liquidia Corporation's litigation battle and upcoming commercial launch of its primary candidate, YUTREPIA, take spotlight. Click to read why LQDA is a Hold.